Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANTHONY PAUL CONLEY and NEETA SOMAIAH.
ANTHONY PAUL CONLEY
Connection Strength
2.869
NEETA SOMAIAH
  1. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter? Cancers (Basel). 2024 Feb 23; 16(5).
    View in: PubMed
    Score: 0.247
  2. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Feb 13.
    View in: PubMed
    Score: 0.247
  3. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med. 2023 02; 12(4):4282-4293.
    View in: PubMed
    Score: 0.224
  4. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.
    View in: PubMed
    Score: 0.222
  5. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother. 2022 10 01; 45(8):374-378.
    View in: PubMed
    Score: 0.222
  6. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma. 2020; 2020:8363986.
    View in: PubMed
    Score: 0.191
  7. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).
    View in: PubMed
    Score: 0.178
  8. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899.
    View in: PubMed
    Score: 0.165
  9. Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. Sarcoma. 2017; 2017:7495914.
    View in: PubMed
    Score: 0.159
  10. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep. 2017 08 25; 7(1):9519.
    View in: PubMed
    Score: 0.158
  11. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol. 2018 09; 4:1-6.
    View in: PubMed
    Score: 0.156
  12. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys. 2024 Mar 15; 118(4):971-978.
    View in: PubMed
    Score: 0.060
  13. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
    View in: PubMed
    Score: 0.058
  14. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 07 15; 129(14):2201-2213.
    View in: PubMed
    Score: 0.058
  15. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.
    View in: PubMed
    Score: 0.057
  16. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484.
    View in: PubMed
    Score: 0.056
  17. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer. 2022 09 15; 128(18):3383-3391.
    View in: PubMed
    Score: 0.055
  18. Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. Adv Radiat Oncol. 2022 May-Jun; 7(3):100913.
    View in: PubMed
    Score: 0.054
  19. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat. 2021 Apr; 186(3):871-882.
    View in: PubMed
    Score: 0.050
  20. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther. 2020 05; 19(5):1165-1172.
    View in: PubMed
    Score: 0.047
  21. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020 02 21; 11(1):1008.
    View in: PubMed
    Score: 0.047
  22. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100.
    View in: PubMed
    Score: 0.040
  23. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 10; 22(10):1271-1277.
    View in: PubMed
    Score: 0.039
  24. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.
    View in: PubMed
    Score: 0.039
  25. Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. Can J Cardiol. 2017 10; 33(10):1335.e13-1335.e15.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.